

Blackstaff Pharmaceuticals Limited

Financial statements

For the year ended 30 September 2008

Company registration number: 03754932

SATURDAY



A1A00B2Y

A48

27/06/2009

246

COMPANIES HOUSE

Blackstaff Pharmaceuticals Limited

Financial statements

<i>Contents</i>	<i>Page</i>
Directors and other information	1
Directors' report	2
Statement of directors' responsibilities in respect of the directors' report and the financial statements	3
Independent auditors' report	4
Profit and loss account	6
Balance sheet	6
Notes to the financial statements	8-11

Blackstaff Pharmaceuticals Limited

Directors and other information

Directors

P Surgenor
N Meier

Secretary

P Surgenor

Registered office

Aquis Court
31 Fishpool Street
St Albans
Hertfordshire
AL3 4RF

Bankers

First Trust Bank
37-41 Cregagh Road
Belfast

Solicitors

Johns Elliot
Solicitors
11 Lombard Street
Belfast

Auditors

KPMG
Stokes House
17/25 College Square East
Belfast

Company registration number

03754932

Blackstaff Pharmaceuticals Limited

Directors' report

The directors have pleasure in submitting their annual report to the shareholders together with the audited financial statements of the company for the year ended 30 September 2008.

Principal activity and business review

The company did not trade during the year. The directors do not expect that this position will change in the foreseeable future.

Directors

The members of the board during the year were:-

P Surgenor
N Meier

Directors' interests in contracts

No director had at any time during the year a material interest in any contract that was significant in relation to the company's business.

Political and charitable contributions

The company made no political or charitable contributions during the year.


Disclosure of information to auditors

The directors who held office at the date of approval of this directors' report confirm that, so far as they are each aware, there is no relevant audit information of which the company's auditors are unaware; and each director has taken all the steps that they ought to have taken as a director to make themselves aware of any relevant audit information and to establish that the company's auditors are aware of that information.

Auditors

Pursuant to Section 487 of the Companies Act 2006, the auditors will be deemed to be reappointed and KPMG will therefore continue in office.

By order of the board


Director

22nd June 2009

Blackstaff Pharmaceuticals Limited

Statement of directors' responsibilities in respect of the directors' report and the financial statements

The directors are responsible for preparing the directors' report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with UK Accounting Standards and applicable law (UK Generally Accepted Accounting Practice).

The financial statements are required by law to give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.


In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that its financial statements comply with the Companies Act 1985. They have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the company and to prevent and detect fraud and other irregularities.

Under applicable law the directors are also responsible for preparing a directors' report that complies with that law.

By order of the board


Director

22nd June 2009



KPMG
Chartered Accountants
Stokes House
17-25 College Square East
Belfast BT1 6DH
Northern Ireland

Independent auditors' report to the members of Blackstaff Pharmaceuticals Limited

We have audited the financial statements of Blackstaff Pharmaceuticals Limited for the year ended 30 September 2008 which comprise the profit and loss account, the balance sheet and the related notes. These financial statements have been prepared under the accounting policies set out therein.

This report is made solely to the company's members, as a body, in accordance with section 235 of the Companies Act 1985. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of directors and auditors

The directors' responsibilities for preparing the financial statements in accordance with applicable law and UK Accounting Standards (UK Generally Accepted Accounting Practice) are set out in the statement of directors' responsibilities on page 3.

Our responsibility is to audit the financial statements in accordance with relevant legal and regulatory requirements and International Standards on Auditing (UK and Ireland).

We report to you our opinion as to whether the financial statements give a true and fair view and are properly prepared in accordance with the Companies Act 1985. We also report to you whether in our opinion the information given in the directors' report is consistent with the financial statements.

In addition we report to you if, in our opinion, the company has not kept proper accounting records, if we have not received all the information and explanations we require for our audit, or if information specified by law regarding directors' remuneration and other transactions is not disclosed.

We read the directors' report and consider implications for our report if we become aware of any apparent misstatements within it.

Basis of audit opinion

We conducted our audit in accordance with International Standards on Auditing (UK and Ireland) issued by the Auditing Practices Board. An audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures in the financial statements. It also includes an assessment of the significant estimates and judgments made by the directors in the preparation of the financial statements, and of whether the accounting policies are appropriate to the company's circumstances, consistently applied and adequately disclosed.

We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or other irregularity or error. In forming our opinion we also evaluated the overall adequacy of the presentation of information in the financial statements.



KPMG
Chartered Accountants
Stokes House
17-25 College Square East
Belfast BT1 6DH
Northern Ireland

Independent auditors' report to the members of Blackstaff Pharmaceuticals Limited *(continued)*

Opinion

In our opinion the financial statements:

- the financial statements give a true and fair view, in accordance with UK Generally Accepted Accounting Practice, of the state of the company's affairs as at 30 September 2008 and of its result for the year then ended; and
- the financial statements have been properly prepared in accordance with the Companies Act 1985; and
- the information given in the directors' report is consistent with the financial statements.

KPMG
Chartered Accountants
Registered Auditor

22nd June 2009

Blackstaff Pharmaceuticals Limited

Profit and Loss account At 30 September 2008

	<i>Note</i>	2008 £	2007 £
Administrative expenses		-	(47)
Operating loss – discontinued operations		-	(47)
Interest payable		-	-
Loss on ordinary activities before taxation	2	-	(47)
Taxation on loss on ordinary activities	3	-	-
Loss for the financial year	7	-	(47)

The company has no recognised gains or losses other than those included above and therefore no separate statement of total recognised gains or losses have been presented.

The notes on pages 8 to 11 form part of these financial statements.

Blackstaff Pharmaceuticals Limited

Balance sheet

At 30 September 2008

	Note	2008	2007
		£	£
Current assets			
Debtors	4	1,000	1,000
Cash at bank		51,460	51,460
		<u>52,460</u>	<u>52,460</u>
Creditors: Amounts falling due within one year	5	(46,769)	(46,769)
		<u>5,691</u>	<u>5,691</u>
Net assets			
		<u>5,691</u>	<u>5,691</u>
Capital and reserves			
Called up share capital	6	1,000	1,000
Profit and loss account	7	4,691	4,691
		<u>5,691</u>	<u>5,691</u>
Shareholders' funds	8	<u>5,691</u>	<u>5,691</u>

The financial statements were approved by the Board on 22nd June 2009 and signed on their behalf by:


Director

The notes on pages 8 to 11 form part of these financial statements.

Blackstaff Pharmaceuticals Limited

Notes

(forming part of the financial statements)

1 Principal accounting policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to these financial statements.

Basis of accounting

The financial statements have been prepared in accordance with the requirements of the Companies (Northern Ireland) Order 1986 under the historical cost convention and comply with financial reporting standards of the Accounting Standards Board.

Under Financial Reporting Standard No.1 'Cash Flow Statements' the Company is exempt from the requirement to prepare a cash flow statement on the grounds that it is a wholly owned subsidiary undertaking. A group cash flow is included in the financial statement of the parent company.

Turnover

Turnover represents invoiced amounts of goods sold net of value added tax and settlement discount.

Going concern

The company has ceased trading. The Directors consider, having taken into account all the information that could reasonably be expected to be available, that the Company will have sufficient cash flow to enable it to meet its liabilities as they fall due for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the Company's financial statements.

Taxation

The charge for taxation is based on the profit for the year.

2 Loss on ordinary activities before taxation

The loss on ordinary activities before taxation is stated after charging/(crediting) the following:

	2008 £	2007 £
Auditors' remuneration – audit services	-	-
– non-audit services	-	-
	<hr/>	<hr/>

Blackstaff Pharmaceuticals Limited

Notes (continued)

3 Taxation on profit on ordinary activities

	2008 £	2007 £
UK Corporation tax		
UK corporation tax on profit of the period	-	-
Adjustments in respect of previous years	-	-
	<hr/>	<hr/>
Total current tax	-	-
Deferred tax		
Origination/reversal of timing differences	-	-
Adjustment in respect of previous years	-	-
	<hr/>	<hr/>
Total deferred tax	-	-
	<hr/>	<hr/>
Tax on loss on ordinary activities	-	-
	<hr/>	<hr/>

Factors affecting the tax charge for the current period

The current tax charge for the period is lower than the standard rate of corporation tax in the UK 28.5%, (2007: 30%). The differences are explained below:

	2008 £	2007 £
Current tax reconciliation		
Loss on ordinary activities before tax	-	(47)
	<hr/>	<hr/>
Current tax at 28.5% (2007: 30%)	-	(14)
Effects of:		
Expenses not deductible for tax purposes	-	14
	<hr/>	<hr/>
Current tax charge	-	-
	<hr/>	<hr/>

Blackstaff Pharmaceuticals Limited

Notes (continued)

4 Debtors	2008	2007
	£	£
Amounts owed by parent undertaking	<u>1,000</u>	<u>1,000</u>
5 Creditors: Amounts falling due within one year	2008	2007
	£	£
Amounts due to parent undertaking	45,338	45,338
Corporation tax	681	681
Accruals	750	750
	<u>46,769</u>	<u>46,769</u>
6 Share capital	2008	2007
	£	£
<i>Authorised:</i>		
1,000,000 ordinary shares of £1 each	<u>1,000,000</u>	<u>1,000,000</u>
<i>Allotted, called up and fully paid:</i>		
1,000 ordinary shares of £1 each	<u>1,000</u>	<u>1,000</u>
7 Profit and loss account	2008	2007
	£	£
At beginning of year	4,691	4,738
Loss for the financial year	-	(47)
At the end of year	<u>4,691</u>	<u>4,691</u>

Blackstaff Pharmaceuticals Limited

Notes (continued)

8 Reconciliation of movement in shareholders' funds

	2008 £	2007 £
Opening shareholders' funds	5,691	5,738
Loss for the financial year	-	(47)
	<hr/>	<hr/>
Closing shareholders' funds	<u>5,691</u>	<u>5,691</u>

9 Group affiliation

The company's immediate parent company is Sangers (Northern Ireland) Limited, a company incorporated in Northern Ireland. The ultimate parent undertaking is United Drug plc, a company incorporated and operating in the Republic of Ireland.

The largest group in which the results of the company are consolidated is that headed by United Drug plc. No other group accounts include the results of the company.

The consolidated accounts of United Drug plc are available to the public and may be obtained from the following address:

The Secretary
United Drug plc
United Drug House
Magna Business Park
Magna Drive
Citywest Road
Dublin 24

10 Related party transactions

Since more than 90% of the company's voting rights are controlled within the United Drug plc group of companies, of which it is a member, the company has taken advantage of the exemption not to disclose transactions with entities that are part of the group.